- Home
- ATNF vs PALI Comparison
ATNF vs PALI Comparison
Compare ATNF & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- PALI
- Stock Information
- Founded
- ATNF 2016
- PALI 1996
- Country
- ATNF United States
- PALI United States
- Employees
- ATNF N/A
- PALI N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATNF Health Care
- PALI Health Care
- Exchange
- ATNF Nasdaq
- PALI Nasdaq
- Market Cap
- ATNF 4.1M
- PALI 3.4M
- IPO Year
- ATNF N/A
- PALI N/A
- Fundamental
- Price
- ATNF $1.20
- PALI $0.84
- Analyst Decision
- ATNF
- PALI Strong Buy
- Analyst Count
- ATNF 0
- PALI 2
- Target Price
- ATNF N/A
- PALI $23.00
- AVG Volume (30 Days)
- ATNF 77.0K
- PALI 139.4K
- Earning Date
- ATNF 03-18-2025
- PALI 03-25-2025
- Dividend Yield
- ATNF N/A
- PALI N/A
- EPS Growth
- ATNF N/A
- PALI N/A
- EPS
- ATNF N/A
- PALI N/A
- Revenue
- ATNF N/A
- PALI N/A
- Revenue This Year
- ATNF N/A
- PALI N/A
- Revenue Next Year
- ATNF $54.15
- PALI N/A
- P/E Ratio
- ATNF N/A
- PALI N/A
- Revenue Growth
- ATNF N/A
- PALI N/A
- 52 Week Low
- ATNF $1.10
- PALI $0.75
- 52 Week High
- ATNF $17.75
- PALI $9.65
- Technical
- Relative Strength Index (RSI)
- ATNF 35.77
- PALI 26.07
- Support Level
- ATNF $1.31
- PALI $0.75
- Resistance Level
- ATNF $1.43
- PALI $0.85
- Average True Range (ATR)
- ATNF 0.09
- PALI 0.06
- MACD
- ATNF 0.00
- PALI 0.01
- Stochastic Oscillator
- ATNF 13.82
- PALI 26.36
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.